AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

755.666

+7.7451.04%

Number of Gainers:17

Number of Losers:12

Number of Flat:16

PE:- -

High:756.356

Open:753.505

Low:749.555

Close:747.921

Volume:43.52M

Turnover:201.05M

Market Cap:114.75B

Float Cap:111.15B

Loading ...

Parmantier & Cie. Initiates 'Buy' Rating on Clinuvel Pharmaceuticals Limited, Sets 12-Month Price Target at AU$26.50

Starpharma and Radiopharm Theranostics Partner to Develop Novel Radiotherapy Asset

Orthocell Appoints First Canadian Distributor for Nerve Repair Product Ahead of Official Launch; Shares Soar 13%

MT Newswires Live

BRIEF-Polynovo Ltd Says Not Affected By Pharma Tariffs

BRIEF-Starpharma Holdings Signs Research And Option Agreement With Radiopharm Theranostics

Dimerix's Drug Candidate to Treat Kidney Disease Receives Orphan Drug Designation in Japan

MT Newswires Live

Starpharma Holdings - Research and Option Agreement With Radiopharm Theranostics

THOMSON REUTERS

Starpharma Holdings - Agreement to Develop Novel Radiotherapy Asset

THOMSON REUTERS

PolyNovo Says Devices Not to be Impacted by New US Tariffs

MT Newswires Live

Dimerix Ltd - Dmx-200 Receives Orphan Drug Designation in Japan

THOMSON REUTERS

Polynovo Ltd - Polynovo Not Affected by Pharma Tariffs-Pnv

THOMSON REUTERS

Polynovo Ltd - Currently Maintains Inventory Sufficient for 12 Months Within US

THOMSON REUTERS

CSL Appoints CFO

MT Newswires Live

Australia's CSL names Ken Lim as CFO from October

BRIEF-Csl Appoints Ken Lim As CFO

CSL Ltd - Appoints Ken Lim as CFO Effective 7 October 2025

THOMSON REUTERS

CSL Ltd - Joy Linton to Step Down as CFO on 7 October 2025

THOMSON REUTERS

ASX Growth Leaders With High Insider Ownership September 2025

Simply Wall St.

Altium And 2 Other High Growth Tech Stocks In Australia

Simply Wall St.

Korean Banks Could Face Capitalization Decline Under Looser Regulations, S&P Says

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK7508/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":755.666,"timestamp":1760072399855,"preClose":747.92145,"halted":0,"volume":43515793,"delay":0,"changeRate":0.010355,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":7.744568,"latestTime":"10-10 16:00:00 AEDT","open":753.5048,"high":756.3559,"low":749.5553,"amount":201050700,"amplitude":0.009093,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1760310000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1760050800000,1760072400000]],"turnoverRate":0.001558,"increases":13,"decrements":13,"flats":17,"marketCap":114748171758,"floatMarketCap":111152797876.5625},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":756.3559,"amplitude":0.009093,"preClose":747.92145,"low":749.5553,"latestPrice":755.666,"volume":43515793,"delay":0,"open":753.5048,"prevYearClose":936.801,"prevWeekClose":749.725,"prevMonthClose":712.826,"prevQuarterClose":712.826,"fiveDayClose":749.725,"twentyDayClose":740.889,"sixtyDayClose":876.9,"secType":"PLATE","market":"AU","turnoverRate":0.001558,"marketCap":114748171758,"floatMarketCap":111152797876.5625,"timestamp":1760072399855,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":17,"down":12,"flat":16},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2571531763","title":"Parmantier & Cie. Initiates 'Buy' Rating on Clinuvel Pharmaceuticals Limited, Sets 12-Month Price Target at AU$26.50","url":"https://stock-news.laohu8.com/highlight/detail?id=2571531763","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571531763?lang=en_us&edition=fundamental","pubTime":"2025-09-30 16:52","pubTimestamp":1759222345,"startTime":"0","endTime":"0","summary":"Parmantier & Cie. GmbH has issued a new research update on CLINUVEL Pharmaceuticals Limited, maintaining a \"Buy\" recommendation with a 12-month target price of AU$26.50. The report highlights CLINUVEL's strategic expansion in the US, including its planned upgrade to a Level II ADR program on Nasdaq by the end of 2025, aimed at increasing its visibility and attracting more institutional investors. Parmantier & Cie. also notes CLINUVEL's operational resilience, particularly its US-based manufacturing capacities, which protect the company from potential import tariffs and ensure robust supply chains. The research underscores CLINUVEL's strong positioning for sustainable international growth.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL9fPGnt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","CUV.AU"],"gpt_icon":0},{"id":"2571954633","title":"Starpharma and Radiopharm Theranostics Partner to Develop Novel Radiotherapy Asset","url":"https://stock-news.laohu8.com/highlight/detail?id=2571954633","media":"Small Caps","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571954633?lang=en_us&edition=fundamental","pubTime":"2025-09-30 10:11","pubTimestamp":1759198273,"startTime":"0","endTime":"0","summary":"The partnership, which follows six months of preliminary research under Starpharma’s Star Navigator drug development program, will see Radiopharm pay Starpharma a $500,000 for an exclusive option to licence the new asset.Starpharma has spent the past 12 months optimising Star Navigator, while showcasing the unique capabilities of dendrimers at high-profile scientific conferences to generate industry interest and open new avenues for collaboration.“The Star Navigator initiative was launched this year to facilitate partnerships by allowing collaborators to access and evaluate the benefits of our technology within their own research and development programs,” Starpharma chief executive officer Cheryl Maley said.“Our engagement with Radiopharm speaks to the value of our technology and will demonstrate how our DEP platform can help shape the future oftargeted cancer therapies.”She added that the collaboration does not impact the progress of Starpharma’s internal development efforts such as ","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/09/Starpharma-Radiopharm-Theranostics-ASX-RAD-SPL-Develop-Novel-Radiotherapy-Asset.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/09/Starpharma-Radiopharm-Theranostics-ASX-RAD-SPL-Develop-Novel-Radiotherapy-Asset.jpg"],"rights":{"source":"smallcap_stock","url":"https://smallcaps.com.au/starpharma-radiopharm-theranostics-partner-develop-novel-radiotherapy-asset/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/starpharma-radiopharm-theranostics-partner-develop-novel-radiotherapy-asset/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["RAD.AU","SPL.AU","BK7096","BK7067","BK7508","BK7501"],"gpt_icon":0},{"id":"2571398773","title":"Orthocell Appoints First Canadian Distributor for Nerve Repair Product Ahead of Official Launch; Shares Soar 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2571398773","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571398773?lang=en_us&edition=fundamental","pubTime":"2025-09-30 09:31","pubTimestamp":1759195901,"startTime":"0","endTime":"0","summary":"Orthocell  appointed its first Canadian distributor for its nerve repair product Remplir ahead of an official in-country launch in early October, according to a Tuesday Australian bourse filing.Approval processes for individual hospitals will be started immediately to facilitate the market entry, per the filing. Exclusive distributorships have been secured for Alberta and British Columbia, and further appointments are expected for other Canadian provinces.The Canadian market launch will be overseen by the firm's existing in-house US-based marketing and medical education teams. Orthocell received a medical device license from Health Canada for the product in April.The firm's shares jumped nearly 13% in recent trading on Tuesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","OCC.AU","BK7508"],"gpt_icon":0},{"id":"2571539871","title":"BRIEF-Polynovo Ltd Says Not Affected By Pharma Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2571539871","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571539871?lang=en_us&edition=fundamental","pubTime":"2025-09-30 09:30","pubTimestamp":1759195826,"startTime":"0","endTime":"0","summary":"BRIEF-Polynovo Ltd Says Not Affected By Pharma TariffsSept 30 (Reuters) - Polynovo Ltd PNV.AX:POLYNOVO NOT AFFECTED BY PHARMA TARIFFSCURRENTLY MAINTAINS INVENTORY SUFFICIENT FOR 12 MONTHS WITHIN USFurther company coverage: PNV.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nFWN3VG0MB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PNV.AU","BK7126","BK7508"],"gpt_icon":0},{"id":"2571239874","title":"BRIEF-Starpharma Holdings Signs Research And Option Agreement With Radiopharm Theranostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2571239874","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571239874?lang=en_us&edition=fundamental","pubTime":"2025-09-30 09:28","pubTimestamp":1759195702,"startTime":"0","endTime":"0","summary":"BRIEF-Starpharma Holdings Signs Research And Option Agreement With Radiopharm TheranosticsSept 30 (Reuters) - Radiopharm Theranostics Ltd RAD.AX:RESEARCH AND OPTION AGREEMENT WITH RADIOPHARM THERANOST","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nFWN3VG0ML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPL.AU","BK7096","BK7067","RAD.AU","BK7501","BK7508"],"gpt_icon":0},{"id":"2571336480","title":"Dimerix's Drug Candidate to Treat Kidney Disease Receives Orphan Drug Designation in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2571336480","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571336480?lang=en_us&edition=fundamental","pubTime":"2025-09-30 07:49","pubTimestamp":1759189755,"startTime":"0","endTime":"0","summary":"Dimerix  said its drug candidate, DMX-200, for the treatment of focal segmental glomerulosclerosis , a serious and rare disease that attacks the kidney, has received Orphan Drug designation in Japan, according to a Tuesday filing with the Australian bourse.Japanese partner FUSO Pharmaceutical Industries has exclusive rights to develop, register, and commercialize DMX-200 to treat FSGS in the Japanese market.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","FSGS","DXB.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2571648713","title":"Starpharma Holdings - Research and Option Agreement With Radiopharm Theranostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2571648713","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571648713?lang=en_us&edition=fundamental","pubTime":"2025-09-30 07:46","pubTimestamp":1759189589,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nFWN3VG0ML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","SPL.AU","RAD.AU","BK7501","BK7067","BK7508"],"gpt_icon":0},{"id":"2571364874","title":"Starpharma Holdings - Agreement to Develop Novel Radiotherapy Asset","url":"https://stock-news.laohu8.com/highlight/detail?id=2571364874","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571364874?lang=en_us&edition=fundamental","pubTime":"2025-09-30 07:46","pubTimestamp":1759189589,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nFWN3VG0ML:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","SPL.AU","BK7067","BK7508","BK7501","BK7096"],"gpt_icon":0},{"id":"2571369067","title":"PolyNovo Says Devices Not to be Impacted by New US Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2571369067","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571369067?lang=en_us&edition=fundamental","pubTime":"2025-09-30 07:13","pubTimestamp":1759187625,"startTime":"0","endTime":"0","summary":"PolyNovo  said its NovoSorb BTM and NovoSorb MTX devices available for sale in the US are only subject to the 10% tariff imposed on exports to the US and will not be affected by the new tariffs on pharmaceutical products, according to a Tuesday filing with the Australian bourse.The medical technology firm also said it has about a year's worth of inventory within the US, with the capacity to increase levels.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PNV.AU","BK7126","BK7508"],"gpt_icon":0},{"id":"2571636603","title":"Dimerix Ltd - Dmx-200 Receives Orphan Drug Designation in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2571636603","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571636603?lang=en_us&edition=fundamental","pubTime":"2025-09-30 06:37","pubTimestamp":1759185439,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nFWN3VG0GN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DXB.AU","BK7501","BK7508","BK7067"],"gpt_icon":0},{"id":"2571660383","title":"Polynovo Ltd - Polynovo Not Affected by Pharma Tariffs-Pnv","url":"https://stock-news.laohu8.com/highlight/detail?id=2571660383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571660383?lang=en_us&edition=fundamental","pubTime":"2025-09-30 06:36","pubTimestamp":1759185408,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nFWN3VG0MB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PNV.AU","BK7126","BK7508"],"gpt_icon":0},{"id":"2571035366","title":"Polynovo Ltd - Currently Maintains Inventory Sufficient for 12 Months Within US","url":"https://stock-news.laohu8.com/highlight/detail?id=2571035366","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571035366?lang=en_us&edition=fundamental","pubTime":"2025-09-30 06:36","pubTimestamp":1759185408,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nFWN3VG0MB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PNV.AU","BK7126","BK7508"],"gpt_icon":0},{"id":"2571366275","title":"CSL Appoints CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2571366275","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571366275?lang=en_us&edition=fundamental","pubTime":"2025-09-30 06:33","pubTimestamp":1759185226,"startTime":"0","endTime":"0","summary":"CSL  has appointed Chief Strategy Officer Ken Lim as chief financial officer, effective Oct. 7, according to a Tuesday filing with the Australian bourse.Lim will succeed Joy Linton, who will step down as CFO on Oct. 7 but will remain with the company for a period to ensure an orderly transition, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","CSL.AU","BK7501","BK7511","XKO.AU","LU1169589451.USD","BK4023","BK7067","LU1169590202.USD","BK4595","LU0728928796.USD","BK4516","XJO.AU","STRK","BK4086","BK4600","BK4585","CSL","SG9999004303.SGD","BK7508","BK4588","BK4596","SGXZ23171101.USD"],"gpt_icon":0},{"id":"2571663803","title":"Australia's CSL names Ken Lim as CFO from October","url":"https://stock-news.laohu8.com/highlight/detail?id=2571663803","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571663803?lang=en_us&edition=fundamental","pubTime":"2025-09-30 06:09","pubTimestamp":1759183768,"startTime":"0","endTime":"0","summary":"Australia's CSL names Ken Lim as CFO from OctoberSept 30 (Reuters) - Australian biotech giant CSL CSL.AX on Tuesday said Ken Lim, its chief strategy officer, will assume the role of chief financial of","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nL3N3VG1GK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK7067","BK7508","CSL.AU","BK7501"],"gpt_icon":0},{"id":"2571366382","title":"BRIEF-Csl Appoints Ken Lim As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2571366382","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571366382?lang=en_us&edition=fundamental","pubTime":"2025-09-30 06:08","pubTimestamp":1759183703,"startTime":"0","endTime":"0","summary":"BRIEF-Csl Appoints Ken Lim As CFOSept 30 (Reuters) - CSL Ltd CSL.AX:APPOINTS KEN LIM AS CFO EFFECTIVE 7 OCTOBER 2025JOY LINTON TO STEP DOWN AS CFO ON 7 OCTOBER 2025Further company coverage: CSL.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nFWN3VG0LJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7511","BK7501","CSL.AU","BK7067"],"gpt_icon":0},{"id":"2571668023","title":"CSL Ltd - Appoints Ken Lim as CFO Effective 7 October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2571668023","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571668023?lang=en_us&edition=fundamental","pubTime":"2025-09-30 06:05","pubTimestamp":1759183511,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nFWN3VG0LJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7511","BK7067","BK7508","CSL.AU"],"gpt_icon":0},{"id":"2571366807","title":"CSL Ltd - Joy Linton to Step Down as CFO on 7 October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2571366807","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571366807?lang=en_us&edition=fundamental","pubTime":"2025-09-30 06:05","pubTimestamp":1759183511,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nFWN3VG0LJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7508","BK7501","BK7067","BK7511"],"gpt_icon":0},{"id":"2571350701","title":"ASX Growth Leaders With High Insider Ownership September 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2571350701","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571350701?lang=en_us&edition=fundamental","pubTime":"2025-09-30 03:08","pubTimestamp":1759172882,"startTime":"0","endTime":"0","summary":"As the Australian market navigates fluctuating foreign direct investment flows and a mixed performance across sectors, investors are closely watching for opportunities amidst these shifts. In this environment, growth companies with high insider ownership can be particularly appealing, as they often indicate strong confidence from those who know the business best.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3112100-choice1-main-header/1585186815935","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3112100-choice1-main-header/1585186815935"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/commercial-services/asx-c79/chrysos-shares/news/asx-growth-leaders-with-high-insider-ownership-september-202","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/commercial-services/asx-c79/chrysos-shares/news/asx-growth-leaders-with-high-insider-ownership-september-202","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["UNI.AU","BK7095","BK7064","GTI.AU","NWF.AU","WZR.AU","TNE.AU","BK7508","BK7116","EIQ.AU","BB1.AU","XKO.AU","BK7050","BK7096","BK7043","ACR.AU","XJO.AU","XAO.AU","BK7158","IMA.AU","BK7093","BK7094","3DP.AU","C79.AU","FND.AU","AV1.AU","BK7016","BK7021","BK7503"],"gpt_icon":0},{"id":"2571035070","title":"Altium And 2 Other High Growth Tech Stocks In Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2571035070","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571035070?lang=en_us&edition=fundamental","pubTime":"2025-09-30 03:05","pubTimestamp":1759172756,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a fluctuating landscape, with the S&P/ASX 200 Index recently flirting with 8,860 points and foreign direct investment outflows heading back to the US, investors are keenly evaluating high-growth opportunities amid shifting sentiments. In this context, identifying promising tech stocks like Altium and others involves assessing their potential for innovation and resilience in an environment where momentum can often outweigh fundamentals.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/software/asx-tne/technology-one-shares/news/altium-and-2-other-high-growth-tech-stocks-in-australia","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-tne/technology-one-shares/news/altium-and-2-other-high-growth-tech-stocks-in-australia","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","IMM.AU","NXL.AU","XAO.AU","XJO.AU","BK7016","BK7067","TNE.AU","BK7503","XKO.AU"],"gpt_icon":0},{"id":"2571382351","title":"Korean Banks Could Face Capitalization Decline Under Looser Regulations, S&P Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2571382351","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571382351?lang=en_us&edition=fundamental","pubTime":"2025-09-29 18:48","pubTimestamp":1759142938,"startTime":"0","endTime":"0","summary":"Korean banks will see weaker capitalization under looser regulatory risk-weight requirements, S&P Global Ratings said in a Monday release.Government efforts to boost banks' corporate financing, such as venture capital investments and allotment to a proposed state-led national growth fund, could increase their exposure to equities and funds, the rating agency said.These measures could dampen the banks' risk-adjusted capital  ratios, with potential downgrades for those with greater risk exposures, according to S&P.The rating agency still expects banks to continue exhibiting modest growth appetite given US trade volatility and parent groups' efforts for higher shareholder payouts.A 10% rise in equity and fund holdings would result in a modest decline in top banks' capitalization, while a doubling of this figure could lead to their average RAC ratio dropping to 7.3%, S&P said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAC.AU","BK7508","RAC","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":110,"code":"91000000","status":"200"}]}}